These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 29212109)

  • 1. Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Klok FA; Ageno W; Barco S; Binder H; Brenner B; Duerschmied D; Empen K; Faggiano P; Ficker JH; Galiè N; Ghuysen A; Held M; Heydenreich N; Huisman MV; Jiménez D; Kozak M; Lang IM; Lankeit M; Münzel T; Petris A; Pruszczyk P; Quitzau K; Schellong S; Schmidt KH; Stefanovic BS; Verschuren F; Wolf-Puetz A; Meyer G; Konstantinides SV;
    Thromb Haemost; 2017 Dec; 117(12):2425-2434. PubMed ID: 29212130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.
    Jacobs A; Kabra R; Das P; Oliphant CS
    Future Cardiol; 2018 Jan; 14(1):89-99. PubMed ID: 29226697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
    Paciaroni M; Agnelli G; Falocci N; Tsivgoulis G; Vadikolias K; Liantinioti C; Chondrogianni M; Bovi P; Carletti M; Cappellari M; Zedde M; Ntaios G; Karagkiozi E; Athanasakis G; Makaritsis K; Silvestrelli G; Lanari A; Ciccone A; Putaala J; Tomppo L; Tatlisumak T; Abdul-Rahim AH; Lees KR; Alberti A; Venti M; Acciarresi M; D'Amore C; Becattini C; Mosconi MG; Cimini LA; Soloperto R; Masotti L; Vannucchi V; Lorenzini G; Tassi R; Guideri F; Acampa M; Martini G; Sohn SI; Marcheselli S; Mumoli N; De Lodovici ML; Bono G; Furie KL; Tadi P; Yaghi S; Toni D; Letteri F; Tassinari T; Kargiotis O; Lotti EM; Flomin Y; Mancuso M; Maccarrone M; Giannini N; Bandini F; Pezzini A; Poli L; Padovani A; Scoditti U; Denti L; Consoli D; Galati F; Sacco S; Carolei A; Tiseo C; Gourbali V; Orlandi G; Giuntini M; Chiti A; Giorli E; Gialdini G; Corea F; Ageno W; Bellesini M; Colombo G; Monaco S; Maimone Baronello M; Karapanayiotides T; Caso V
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29220330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery.
    Litwinowicz R; Konstanty-Kalandyk J; Goralczyk T; Bartus K; Mazur P
    J Thromb Thrombolysis; 2018 Jan; 45(1):9-12. PubMed ID: 29222699
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring.
    Poli S; Härtig F; Spencer C; Ebner M; Birschmann I; Kuhn J; Faix S; Ziemann U; Häring HU; Lehmann R; Peter A; Hörber S
    Thromb Haemost; 2017 Dec; 117(12):2369-2375. PubMed ID: 29212124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
    Uyhazi KE; Miano T; Pan W; VanderBeek BL
    JAMA Ophthalmol; 2018 Feb; 136(2):122-130. PubMed ID: 29242919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
    N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
    Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
    Henk HJ; Cao F; Tuell K; Price K; Singh P; Mardekian J; Odell K; Patel C; Tan W; Sands GH; Singhal S; Trocio J; Vo L
    Curr Med Res Opin; 2018 Mar; 34(3):539-546. PubMed ID: 29235900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation decision support tool: Population perspective.
    Eckman MH; Costea A; Attari M; Munjal J; Wise RE; Knochelmann C; Flaherty ML; Baker P; Ireton R; Harnett BM; Leonard AC; Steen D; Rose A; Kues J
    Am Heart J; 2017 Dec; 194():49-60. PubMed ID: 29223435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
    Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Lip GYH;
    Thromb Haemost; 2017 Dec; 117(12):2376-2388. PubMed ID: 29212125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?
    Chan NC; Weitz JI
    Thromb Haemost; 2017 Dec; 117(12):2213-2214. PubMed ID: 29212109
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post-partum women.
    Ayuk P; Kampouraki E; Truemann A; Sidgwick F; McDonald L; Bingham J; Murphy P; Kamali F
    Am J Hematol; 2020 Jan; 95(1):E10-E13. PubMed ID: 31599003
    [No Abstract]   [Full Text] [Related]  

  • 18. Ecarin based coagulation testing.
    Gosselin RC; Douxfils J
    Am J Hematol; 2020 Jul; 95(7):863-869. PubMed ID: 32350907
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.